20mg vial reference table The 20mg vial shines during the escalation and maintenance phases
Pennsylvanias Medicaid spending for GLP-1s like Ozempic, Wegovy, and Zepbound exploded to an estimated $1.3 billion last year from $233 million in 2022, the year before Medicaid started covering the drugs for obesity
In light of this information, NCL offers this advice to consumers when considering GLP-1 treatment options: Before seeking treatment with a GLP-1 drug, talk to your doctor or health provider to determine if you are a candidate for treatment based on your risk factors and degree of obesity
The goal is sustainable weight loss that can be maintained long term rather than dramatic short-term changes
What that means for you: the category is scientifically grounded but not fully mapped at the product level
Factors that influence how quickly you notice changes How fast you see changes when taking a GLP-1 can depend on many factors and everyones body responds differently